The Abiomed Breethe OXY-1 system is an all-in-one, compact cardiopulmonary bypass system. It provides cardiopulmonary bypass support for people whose lungs are no longer able to supply significant oxygen to their bodies’ organs.
The clearance allows the use of the Breethe OXY-1 to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass for up to six hours.
When used with Abiomed’s Impella heart pump, the Breethe OXY-1 can unload the heart and oxygenate the body, a combination therapy known as ECpella. Think life-sustaining support for people suffering from cardiogenic shock or respiratory failure due to ARDS, H1N1, SARS or COVID-19.
“This ECMO technology will allow us to support new patient populations, such as COVID-19 patients and others who need lung support, and provide combination ECpella therapy to Impella patients who need oxygenation. Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices,” Abiomed CEO Michael R. Minogue said in a news release.